GlassScriptPhysician profile
Patricia A Odonnell
NPI 1316012560
$4,337.80
in general payments reported to CMS, 2019-2025
36 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $683 · 2021: $1,150 · 2022: $798 · 2023: $334 · 2024: $267 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $945.14 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.19 | 2019-2022 | |
| Novo Nordisk INC | $474.90 | 2019-2025 | Wegovy |
| Amgen INC. | $265.77 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $263.21 | 2019-2022 | |
| Abbvie INC. | $211.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $171.33 | 2019-2025 | Airsupra |
| Exact Sciences Corporation | $154.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Rxsight INC | $114.24 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Amarin Pharma, INC. | $102.20 | 2019-2021 | |
| Mannkind Corporation | $96.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $94.85 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $87.63 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Abbott Laboratories | $83.10 | 2022 | |
| Pfizer INC. | $81.97 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $69.58 | 2020 | |
| Radius Health, INC. | $68.10 | 2019-2020 | |
| Baxter Healthcare | $62.38 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $49.12 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $44.59 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $43.16 | 2021-2022 | |
| Corcept Therapeutics | $34.42 | 2019 | |
| Xeris Pharmaceuticals, INC. | $30.52 | 2020-2021 | |
| Clarus Therapeutics INC. | $28.79 | 2021 | |
| Tandem Diabetes Care, INC. | $26.95 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $25.69 | 2021 | |
| Eusa Pharma (US) LLC | $22.47 | 2022 | |
| Glaxosmithkline, LLC. | $22.45 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.69 | 2021 | |
| Ibsa Pharma INC. | $19.65 | 2021 | |
| Zealand Pharma US, INC. | $19.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.12 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.17 | 2022 | |
| Lifescan, INC. | $14.90 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Odonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.